HCW Biologics is trading 13.89% down now at $2.17, extending declines after its August 14, 2026 second-quarter results raised funding and business-continuity concerns.
- Reported a $5.2 million quarterly net loss, only $741,324 in cash, and significant current liabilities.
- The August 18, 2026 decline also came amid broader risk-off trading, with the Nasdaq down 1.44% and S&P 500 down 0.70%.
- Recent earnings and the liquidity warning remain the clearest catalyst.